With allergy misdiagnosis affecting nearly half of Europeans, Lithuania’s Self.co secures €2.56 million to make testing accessible

November 11, 2025 at 01:00 PM UTC
EU-Startups
Original: EN
With allergy misdiagnosis affecting nearly half of Europeans, Lithuania’s Self.co secures €2.56 million to make testing accessible

Lithuanian digital health company Self.co has secured €2.56 million in funding to expand its allergy and food intolerance testing platform. The company aims to make allergy testing more accessible across Europe, addressing the challenge of widespread misdiagnosis. This investment highlights a growing trend of funding for digital health solutions within the European tech sector. The funding round comprises a €1.2 million venture capital investment led by Iron Wolf Capital, along with a €1.36 million grant from the Innovation Agency Lithuania. Self.co's technology utilizes proprietary microarray tests to analyze 98 allergens and 220 food sensitivities using a simple blood sample. This approach offers a more accessible and cost-effective alternative to traditional diagnostic methods. This investment will support Self.co's expansion into new markets, including the UK, Ireland, Austria, and Germany, while also deepening collaborations in Poland and Lithuania. The company's focus on integrating molecular allergy testing with digital symptom management reflects a shift towards data-driven healthcare. This expansion contributes to the development of a strong European digital health ecosystem.

To provide multilingual access, this article summary was automatically generated.

Source Information

Publication: EU-Startups
Published: November 11, 2025 at 01:00 PM UTC
All rights remain with the original publisher.